| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 08/14/2007 | US7256192 Aromatic diamide derivatives, chemicals for agricultural or horticultural use and usage thereof |
| 08/14/2007 | US7256191 Materials and methods for the treatment of depression |
| 08/14/2007 | US7256190 Thiazole compounds useful as inhibitors of protein kinase |
| 08/14/2007 | US7256189 3-(4-amidopyrrol-2-ylmethylidene)-2-indolinone der derivatives as protein kinase inhibitors |
| 08/14/2007 | US7256188 3-aminoalkyl-2-aryl-indole derivatives and their use as GnRH antagonists |
| 08/14/2007 | US7256187 E.g., 11-Dideoxy-4,11-dihydroxyiminorifamycin S and (R/S)-3-[4-(3-Carboxy-1-cyclopropyl-6-fluoro-8-methoxy-4-oxo-1,4-dihydroquinolin-7-yl)-2-methyl-piperazin-1-yl-aminomethylenyl]-11-deoxy-11-hydroxyiminorifamycin SV; especially effective against rifamycin-resistant microbes |
| 08/14/2007 | US7256186 Alzheimer's disease, or other diseases relating to amyloid deposits; neurodegenerative diseases |
| 08/14/2007 | US7256185 Control of selective estrogen receptor modulators |
| 08/14/2007 | US7256184 analyzing concentration of carbonic anhydrase isozymes in tissues, blood or cerebrospinal fluid of patients, than administering proenzymes or drugs that promotes the natural generation of the cell-specific carbonic anhydrase enzymes; aging resistance |
| 08/14/2007 | US7256183 Administering a nucleotide receptor agonist (such as adenosine triphophate or uridine triphosphate); sinusitis, rhinitis, conjunctivitis, asthma, dermatitis, inflammatory collagen vascular diseases, glomerulonephritis; antiallergens |
| 08/14/2007 | US7256179 Oligonucleotides for treating drug resistant HBV infections that may contain contain one or more alkylphosphonate, phosphorothioate, phosphorodithioate, alkylphosphonothioate, phosphoroamidate, carbamate, carbonate, phosphate trimester, acetamidate, carboxymethyl ester linkage nucleotide linkages |
| 08/14/2007 | US7256178 Physiologically active substances |
| 08/14/2007 | US7256177 Lincomycin derivatives possessing antibacterial activity |
| 08/14/2007 | US7256158 Animal husbandry; veterinary medicine |
| 08/14/2007 | US7256043 Transfection complexes |
| 08/14/2007 | US7256005 Treating a hepatitis C virus infection with a N-alkylated pyrrolidines, or piperidines, an inhibitor of HCV p7 protein, preventing p7 protein to permeabilize membranes; a kit contains amantadine viricides |
| 08/14/2007 | US7255984 Combination therapy for osteoporosis |
| 08/14/2007 | US7255882 Enkephalinase inhibitor and GABA precursor loading as anti-anxiety compositions |
| 08/14/2007 | US7255881 For therapy of undesirable skin conditions |
| 08/14/2007 | US7255878 Stable benzimidazole formulation |
| 08/14/2007 | US7255876 Composition comprises sustained-release fine particles and manufacturing method thereof |
| 08/14/2007 | US7255868 Hybrid immunomodulatory peptide and nucleotide sequences for treating allergies |
| 08/14/2007 | US7255853 for topical use for protecting the skin and the hair |
| 08/14/2007 | US7255813 Having a redox potential of below -180 mV and an isolated chlorophyll having a standard redox potential below the that of the first compound as a stabilizer; may also contain Vitamin B or tocotrienol as an oxygen-sequestering substance |
| 08/14/2007 | CA2536543A1 Light activated osteoinductive bone material |
| 08/14/2007 | CA2421302C 4-halogenated 17-methylene steroids, method for the production thereof and pharmaceutical compositions containing these compounds |
| 08/14/2007 | CA2390189C Methods and pharmaceutical compositions for preventing problem behaviors of companion animals |
| 08/14/2007 | CA2370030C Sodium channel blocker compositions and the use thereof |
| 08/14/2007 | CA2354047C Method for the treatment of inflammation |
| 08/14/2007 | CA2334656C Method for preparing aloin by extraction |
| 08/14/2007 | CA2332514C Broad spectrum microbicidal and spermicidal compositions, devices and methods |
| 08/14/2007 | CA2307547C Chronotherapeutic diltiazem formulations and the administration thereof |
| 08/14/2007 | CA2281708C Process for preparing eprosartan |
| 08/14/2007 | CA2251016C .alpha.1-adrenergic receptor antagonists |
| 08/14/2007 | CA2239624C Treatment of negative and cognitive symptoms of schizophrenia with glycine uptake antagonists |
| 08/14/2007 | CA2239421C Composition and method for reducing recovery time in anaesthetised mammals |
| 08/14/2007 | CA2223414C Heteroaryl diol acids as leukotriene antagonists |
| 08/14/2007 | CA2223259C Pharmaceutical formulations of highly lipophilic camptothecin derivatives |
| 08/14/2007 | CA2223176C Novel kappa receptor selective opioid peptides |
| 08/14/2007 | CA2213714C Phenyl-substituted alkenylcarboxylic acid guanidides, process for their preparation, their use as a medicament or diagnostic, and medicament containing them |
| 08/14/2007 | CA2206758C Ortho-substituted benzoylguanidines, process for their preparation, their use as a medicament or diagnostic, and medicament containing them |
| 08/14/2007 | CA2193398C Benzocycloalkene compounds, their production and use |
| 08/14/2007 | CA2173504C Composition for drug delivery comprising nicotine or a derivative thereof and starch microspheres and method for the manufacturing thereof |
| 08/14/2007 | CA2166328C Prostacyclin synthase derived from human |
| 08/14/2007 | CA2150937C Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease |
| 08/14/2007 | CA2128372C Maltose-trehalose converting enzyme, and preparation and uses thereof |
| 08/09/2007 | WO2007090162A2 OXYLIPINS FROM STEARIDONIC ACID AND γ-LINOLENIC ACID AND METHODS OF MAKING AND USING THE SAME |
| 08/09/2007 | WO2007090095A2 Synthesis of carotenoid analogs or derivatives with improved antioxidant characteristics |
| 08/09/2007 | WO2007090068A2 Cyanoisoquinoline compounds that stabilize hypoxia inducible factor (hif) |
| 08/09/2007 | WO2007089934A2 Methods of treating alcoholism and alcohol related disorders using combination drug therapy and swellable polymers |
| 08/09/2007 | WO2007089931A1 Vitamin e succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof |
| 08/09/2007 | WO2007089904A2 Pyridylphenyl compounds for inflammation and immune-related uses |
| 08/09/2007 | WO2007089902A2 Compositions and methods for promoting the healing of tissue of multicellular organisms |
| 08/09/2007 | WO2007089870A2 Vaccine delivery compositions and methods of use |
| 08/09/2007 | WO2007089857A2 Substituted imidazole derivatives and their use as ptpase inhibitors |
| 08/09/2007 | WO2007089787A2 Compositions and methods for treating cardiovascular, cerebrovascular and other vascular disease patients |
| 08/09/2007 | WO2007089780A2 Bmx/etk tyrosine kinase gene therapy materials and methods |
| 08/09/2007 | WO2007089774A2 Compositions and methods for treating cognitive disorders |
| 08/09/2007 | WO2007089743A2 Potassium channel inhibitors |
| 08/09/2007 | WO2007089735A2 Potassium channel inhibitors |
| 08/09/2007 | WO2007089731A2 Ocular fluid markers |
| 08/09/2007 | WO2007089716A2 Use of aminopyrimidine compounds in the treatment of immune disorders |
| 08/09/2007 | WO2007089715A2 Method for treatment of neuropathic pain |
| 08/09/2007 | WO2007089703A2 Methods and compositions for ameliorating or inhibiting decline in memory or intelligence or improving same |
| 08/09/2007 | WO2007089685A2 Compositions and methods for inducing adipose tissue cell death |
| 08/09/2007 | WO2007089683A1 Amido compounds and their use as pharmaceuticals |
| 08/09/2007 | WO2007089679A2 Potassium channel inhibitors |
| 08/09/2007 | WO2007089670A2 Enterically coated cysteamine, cystamine and derivatives thereof |
| 08/09/2007 | WO2007089667A1 Compounds and compositions as ppar modulators |
| 08/09/2007 | WO2007089657A2 Crystalline forms of a farnesyl dibenzodiazepinone |
| 08/09/2007 | WO2007089655A1 Occupant classification system |
| 08/09/2007 | WO2007089646A1 Kinase inhibitors and methods of use thereof |
| 08/09/2007 | WO2007089634A2 Inhibitors of fatty acid synthase (fas) |
| 08/09/2007 | WO2007089626A2 Anabaseine derivatives, pharmaceutical compositions and methods of use thereof |
| 08/09/2007 | WO2007089617A2 Methods, compositions, and kits for the treatment of musculoskeletal disorders and symptoms associated therewith |
| 08/09/2007 | WO2007089616A2 Inhibiting amyloid-beta peptide/rage interaction at the blood-brain barrier |
| 08/09/2007 | WO2007089577A2 Method of reversing, preventing, delaying or stabilizing soft tissue calcification |
| 08/09/2007 | WO2007089571A2 Method of treating chronic kidney disease |
| 08/09/2007 | WO2007089557A2 Polycyclic 1, 2, 3, 4 -tetrahydro- isoquinoline derivatives and compositions comprising them as ppar modulators |
| 08/09/2007 | WO2007089548A2 Compounds and methods for modulating protein trafficking |
| 08/09/2007 | WO2007089512A1 Glucokinase activators |
| 08/09/2007 | WO2007089511A2 Fast acting inhibitor of gastric acid secretion |
| 08/09/2007 | WO2007089507A1 A3 adenosine receptor allosteric modulators |
| 08/09/2007 | WO2007089490A1 Sterilized nanoparticulate glucocorticosteroid formulations |
| 08/09/2007 | WO2007089476A2 Chemoprevention of endometrial cancer |
| 08/09/2007 | WO2007089462A2 Piperidine and piperazine derivatives |
| 08/09/2007 | WO2007089336A2 Certain chemical entities, compositions and methods |
| 08/09/2007 | WO2007089310A1 Bipartite inhibitors of bacterial rna polymerase |
| 08/09/2007 | WO2007089291A2 Estrogen receptor modulators |
| 08/09/2007 | WO2007089247A1 Oxcarbazepine pharmaceutical formulation and its method of preparation, wherein oxcarbazepine has a broad and multi-modal particle size distribution |
| 08/09/2007 | WO2007089193A1 A process for preparing 2-hydroxy-3- [5- (morpholin-4-ylmethyl)pyridin-2-yl] lh-indole-5-carbonitrile as a free base or salts thereof |
| 08/09/2007 | WO2007089192A1 Pharmaceutical use of 2-hydroxy-3- [5- (morpholin-4- ylmethyl) pyridine-2-yl] -1h- indole-5-carbonitrile as a free base or salts |
| 08/09/2007 | WO2007089191A1 New citrate salt of an indole derivative and its pharmaceutical use |
| 08/09/2007 | WO2007089166A1 Medicinal preparation for jugulating a systemic inflammatory response syndrome |
| 08/09/2007 | WO2007089150A1 Means and methods for influencing interactions between dc-sign and dc-sign ligands |
| 08/09/2007 | WO2007089149A2 Water-soluble cc-1065 analogs and their conjugates |
| 08/09/2007 | WO2007089133A1 Means and methods for influencing interactions between dc-sign and dc-sign ligands |
| 08/09/2007 | WO2007089103A1 Composition for inhibiting adhesion |
| 08/09/2007 | WO2007089101A1 Novel benzamidine derivatives, process for the preparation thereof and pharmaceutical composition comprising the same |
| 08/09/2007 | WO2007089051A1 Composition for treating cancer comprising oligonucleotide and non-toxic lps |